UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (21), p.2801

2003

Volltextzugriff (PDF)

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

HIV medicine, 2014-08, Vol.15 (7), p.431-441

2014

Volltextzugriff (PDF)

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Journal of acquired immune deficiency syndromes (1999), 2005-12, Vol.40 (4), p.404-412

2005

Volltextzugriff (PDF)

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.572-580

2014

Volltextzugriff (PDF)

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Journal of acquired immune deficiency syndromes (1999), 2009-04, Vol.50 (4), p.367-374

2009

Volltextzugriff (PDF)

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

The lancet HIV, 2018-01, Vol.5 (1), p.e23-e34

2018

Volltextzugriff (PDF)

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

Clinical infectious diseases, 2006-11, Vol.43 (10), p.1337-1346

2006

Volltextzugriff (PDF)

High prevalence of unintended pregnancies in HIV‐positive women of reproductive age in Ontario, Canada: a retrospective study

HIV medicine, 2012-02, Vol.13 (2), p.107-117

2012

Volltextzugriff (PDF)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

AIDS (London), 2009-11, Vol.23 (17), p.2289-2300

2009

Volltextzugriff (PDF)

Fragility fractures and bone mineral density in HIV positive women : a case-control population-based study

Osteoporosis international, 2007-10, Vol.18 (10), p.1345-1353

2007

Volltextzugriff (PDF)

Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study

International journal of epidemiology, 2010-10, Vol.39 (5), p.1162-1169

2010

Volltextzugriff (PDF)

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

Pediatrics (Evanston), 2009-05, Vol.123 (5), p.1360-1368

2009

Volltextzugriff (PDF)

Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis

The Journal of infectious diseases, 2012-04, Vol.205 (8), p.1230-1238

2012

Volltextzugriff (PDF)

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

The Journal of infectious diseases, 2020-07, Vol.222 (Supplement_1), p.S8-S19

2020

Volltextzugriff (PDF)

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

AIDS (London), 2010-08, Vol.24 (13), p.2019-2027

2010

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

The lancet HIV, 2020-01, Vol.7 (1), p.e16-e26

2020

Volltextzugriff (PDF)

Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management

Clinical microbiology and infection, 2009-07, Vol.15 (7), p.662-669

2009

Volltextzugriff (PDF)

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral‐treated HIV/hepatitis C virus‐coinfected patients

HIV medicine, 2015-01, Vol.16 (1), p.24-31

2015

Volltextzugriff (PDF)

Opioid use and risk of liver fibrosis in HIV/hepatitis C virus‐coinfected patients in Canada

HIV medicine, 2016-01, Vol.17 (1), p.36-45

2016

Volltextzugriff (PDF)

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression

Journal of acquired immune deficiency syndromes (1999), 2010-12, Vol.55 (4), p.451-459

2010

Volltextzugriff (PDF)

Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients

AIDS (London), 2012-09, Vol.26 (14), p.1789-1794

2012

Volltextzugriff (PDF)

Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy—Naive Patients

The Journal of infectious diseases, 2004-07, Vol.190 (2), p.280-284

2004

Volltextzugriff (PDF)

Daily versus weekly azithromycin in cystic fibrosis patients

The European respiratory journal, 2007-09, Vol.30 (3), p.487-495

2007

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

ThemaFemale

ThemaInfectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality

High prevalence of unintended pregnancies in HIV‐positive women of reproductive age in Ontario, Canada: a retrospective study

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Fragility fractures and bone mineral density in HIV positive women : a case-control population-based study

Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral‐treated HIV/hepatitis C virus‐coinfected patients

Opioid use and risk of liver fibrosis in HIV/hepatitis C virus‐coinfected patients in Canada

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression

Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients

Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy—Naive Patients

Daily versus weekly azithromycin in cystic fibrosis patients

Aktive Filter

Suchergebnisse filtern